Cargando…

1553. Infectious Complications Following Hematopoietic Cell Transplantation in Patients With Primary Immunodeficiency Diseases

BACKGROUND: Hematopoietic cell transplantation (HCT) has significantly improved long-term survival for children with primary immunodeficiency diseases (PID). Little is known about specific risk factors for infections after transplant in PID patients and differences from others undergoing HCT. Factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Vora, Surabhi, Englund, Janet, Petrovic, Aleksandra, Woolfrey, Anne, Mallhi, Kanwaldeep, Burroughs, Lauri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252415/
http://dx.doi.org/10.1093/ofid/ofy210.1381
_version_ 1783373258682269696
author Vora, Surabhi
Englund, Janet
Petrovic, Aleksandra
Woolfrey, Anne
Mallhi, Kanwaldeep
Burroughs, Lauri
author_facet Vora, Surabhi
Englund, Janet
Petrovic, Aleksandra
Woolfrey, Anne
Mallhi, Kanwaldeep
Burroughs, Lauri
author_sort Vora, Surabhi
collection PubMed
description BACKGROUND: Hematopoietic cell transplantation (HCT) has significantly improved long-term survival for children with primary immunodeficiency diseases (PID). Little is known about specific risk factors for infections after transplant in PID patients and differences from others undergoing HCT. Factors impacting success of HCT in PID include age at HCT, underlying genetic defect, type of donor and conditioning regimen, and importantly, the presence of pre-existing infection. We describe the epidemiology and risk factors for bacterial, viral and fungal infections in patients undergoing HCT for PID. METHODS: After IRB approval, medical records of patients undergoing HCT at Seattle Children’s Hospital for PID between 1998 and 2017 were reviewed. Donor and stem cell source, conditioning regimen, development of graft vs. host disease (GVHD), chimerism and mortality were considered, in addition to details of pre-HCT infections. Timing, character and treatment details of each incident infection during 12 months post-HCT were collected. Standardized antimicrobial prophylactic regimens were administered. Primary outcomes included mortality and infection-free survival. Kaplan–Meier curves were used to examine infection-free survival, by diagnosis and by HCT era. RESULTS: Sixty-nine patients with PID underwent HCT during the study period. Mean age at HCT was 6.2 years and varied by underlying PID. Altogether, 24 children (34.8%) had severe combined immune deficiency (SCID), 14 (20.3%) had chronic granulomatous disease (CGD), nine (13%) had combined immune deficiency (CID), and six (8.7%) had hyper IgM syndrome. Fifty-six patients received HLA-matched grafts. Umbilical cord blood was utilized in 10% of patients. Acute GVHD grades II–IV developed in 46 (67%) patients. Bacterial infections were the most common infection post-HCT, followed by respiratory and herpes group viral infections. Overall mortality at 1 year was 19%, of which at least 50% was infection related. CONCLUSION: Infection occurs frequently and contributes to morbidity and mortality in patients undergoing HCT for PID. Understanding the timing of infections and contributing risk factors could help develop preemptive and monitoring strategies to improve outcomes in this patient population. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6252415
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62524152018-11-28 1553. Infectious Complications Following Hematopoietic Cell Transplantation in Patients With Primary Immunodeficiency Diseases Vora, Surabhi Englund, Janet Petrovic, Aleksandra Woolfrey, Anne Mallhi, Kanwaldeep Burroughs, Lauri Open Forum Infect Dis Abstracts BACKGROUND: Hematopoietic cell transplantation (HCT) has significantly improved long-term survival for children with primary immunodeficiency diseases (PID). Little is known about specific risk factors for infections after transplant in PID patients and differences from others undergoing HCT. Factors impacting success of HCT in PID include age at HCT, underlying genetic defect, type of donor and conditioning regimen, and importantly, the presence of pre-existing infection. We describe the epidemiology and risk factors for bacterial, viral and fungal infections in patients undergoing HCT for PID. METHODS: After IRB approval, medical records of patients undergoing HCT at Seattle Children’s Hospital for PID between 1998 and 2017 were reviewed. Donor and stem cell source, conditioning regimen, development of graft vs. host disease (GVHD), chimerism and mortality were considered, in addition to details of pre-HCT infections. Timing, character and treatment details of each incident infection during 12 months post-HCT were collected. Standardized antimicrobial prophylactic regimens were administered. Primary outcomes included mortality and infection-free survival. Kaplan–Meier curves were used to examine infection-free survival, by diagnosis and by HCT era. RESULTS: Sixty-nine patients with PID underwent HCT during the study period. Mean age at HCT was 6.2 years and varied by underlying PID. Altogether, 24 children (34.8%) had severe combined immune deficiency (SCID), 14 (20.3%) had chronic granulomatous disease (CGD), nine (13%) had combined immune deficiency (CID), and six (8.7%) had hyper IgM syndrome. Fifty-six patients received HLA-matched grafts. Umbilical cord blood was utilized in 10% of patients. Acute GVHD grades II–IV developed in 46 (67%) patients. Bacterial infections were the most common infection post-HCT, followed by respiratory and herpes group viral infections. Overall mortality at 1 year was 19%, of which at least 50% was infection related. CONCLUSION: Infection occurs frequently and contributes to morbidity and mortality in patients undergoing HCT for PID. Understanding the timing of infections and contributing risk factors could help develop preemptive and monitoring strategies to improve outcomes in this patient population. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6252415/ http://dx.doi.org/10.1093/ofid/ofy210.1381 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Vora, Surabhi
Englund, Janet
Petrovic, Aleksandra
Woolfrey, Anne
Mallhi, Kanwaldeep
Burroughs, Lauri
1553. Infectious Complications Following Hematopoietic Cell Transplantation in Patients With Primary Immunodeficiency Diseases
title 1553. Infectious Complications Following Hematopoietic Cell Transplantation in Patients With Primary Immunodeficiency Diseases
title_full 1553. Infectious Complications Following Hematopoietic Cell Transplantation in Patients With Primary Immunodeficiency Diseases
title_fullStr 1553. Infectious Complications Following Hematopoietic Cell Transplantation in Patients With Primary Immunodeficiency Diseases
title_full_unstemmed 1553. Infectious Complications Following Hematopoietic Cell Transplantation in Patients With Primary Immunodeficiency Diseases
title_short 1553. Infectious Complications Following Hematopoietic Cell Transplantation in Patients With Primary Immunodeficiency Diseases
title_sort 1553. infectious complications following hematopoietic cell transplantation in patients with primary immunodeficiency diseases
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252415/
http://dx.doi.org/10.1093/ofid/ofy210.1381
work_keys_str_mv AT vorasurabhi 1553infectiouscomplicationsfollowinghematopoieticcelltransplantationinpatientswithprimaryimmunodeficiencydiseases
AT englundjanet 1553infectiouscomplicationsfollowinghematopoieticcelltransplantationinpatientswithprimaryimmunodeficiencydiseases
AT petrovicaleksandra 1553infectiouscomplicationsfollowinghematopoieticcelltransplantationinpatientswithprimaryimmunodeficiencydiseases
AT woolfreyanne 1553infectiouscomplicationsfollowinghematopoieticcelltransplantationinpatientswithprimaryimmunodeficiencydiseases
AT mallhikanwaldeep 1553infectiouscomplicationsfollowinghematopoieticcelltransplantationinpatientswithprimaryimmunodeficiencydiseases
AT burroughslauri 1553infectiouscomplicationsfollowinghematopoieticcelltransplantationinpatientswithprimaryimmunodeficiencydiseases